StockData

Aclaris Therapeutics vs Eloxx Pharmaceuticals

ACRS and ELOX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACRS and ELOX compare

Aclaris Therapeutics is the larger company, worth 10 times as much as Eloxx Pharmaceuticals ($531M against $51.5M).

Aclaris Therapeutics grew revenue faster over the last twelve months (−51.0% versus −100% for Eloxx Pharmaceuticals).

Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 5 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACRSELOX
Size and price
Market cap$531M$51.5M
Share price$3.60$12.75
Change, 1 year55.4%1158990%
Change, 5 years−71.4%−97.9%
Beta (5Y)0.96–
Employees737
StockData Score
Total score57 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S64.6×–
P/B4.3×1.1× (better)
FCF yield−11.7%–
Fair value$1.42–
Margin of safety−155%–
Growth
Revenue growth (TTM)−51.0% (better)−100%
Revenue growth, 5Y average3.8%–
Profitability
Gross margin79.5%–
Operating margin−1050%–
Net margin−921%–
FCF margin−757%–
Return on equity−59.1%−54.3% (better)
Financial health
Debt / equity0.000.00
Current ratio3.463.74 (better)
Altman Z-score−3.16 (better)−4.46
Piotroski F-score33
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.3%71.8%
Held by insiders13.3%42.6%
Insider net buying, 12 months−$1.4M–
Short interest, % of float9.1%2.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.